Show simple item record

dc.contributor.authorGiovannoni, G
dc.contributor.authorButzkueven, H
dc.contributor.authorDhib-Jalbut, S
dc.contributor.authorHobart, J
dc.contributor.authorKobelt, G
dc.contributor.authorPepper, G
dc.contributor.authorSormani, MP
dc.contributor.authorThalheim, C
dc.contributor.authorTraboulsee, A
dc.contributor.authorVollmer, T
dc.date.accessioned2016-10-03T13:41:27Z
dc.date.available2016-10-03T13:41:27Z
dc.date.issued2016-09
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.otherS1
dc.identifier.urihttp://hdl.handle.net/10026.1/5548
dc.descriptionpublisher: Elsevier articletitle: Brain health: time matters in multiple sclerosis journaltitle: Multiple Sclerosis and Related Disorders articlelink: http://dx.doi.org/10.1016/j.msard.2016.07.003 content_type: article copyright: © 2016 Oxford PharmaGenesis Ltd. Published by Elsevier B.V.
dc.description.abstract

INTRODUCTION: We present international consensus recommendations for improving diagnosis, management and treatment access in multiple sclerosis (MS). Our vision is that these will be used widely among those committed to creating a better future for people with MS and their families. METHODS: Structured discussions and literature searches conducted in 2015 examined the personal and economic impact of MS, current practice in diagnosis, treatment and management, definitions of disease activity and barriers to accessing disease-modifying therapies (DMTs). RESULTS: Delays often occur before a person with symptoms suggestive of MS sees a neurologist. Campaigns to raise awareness of MS are needed, as are initiatives to improve access to MS healthcare professionals and services. We recommend a clear treatment goal: to maximize neurological reserve, cognitive function and physical function by reducing disease activity. Treatment should start early, with DMT and lifestyle measures. All parameters that predict relapses and disability progression should be included in the definition of disease activity and monitored regularly when practical. On suboptimal control of disease activity, switching to a DMT with a different mechanism of action should be considered. A shared decision-making process that embodies dialogue and considers all appropriate DMTs should be implemented. Monitoring data should be recorded formally in registries to generate real-world evidence. In many jurisdictions, access to DMTs is limited. To improve treatment access the relevant bodies should consider all costs to all parties when conducting economic evaluations and encourage the continuing investigation, development and use of cost-effective therapeutic strategies and alternative financing models. CONCLUSIONS: The consensus findings of an international author group recommend a therapeutic strategy based on proactive monitoring and shared decision-making in MS. Early diagnosis and improved treatment access are also key components.

dc.format.extentS5-S48
dc.format.mediumPrint-Electronic
dc.languageen
dc.language.isoen
dc.publisherElsevier BV
dc.subjectMultiple sclerosis
dc.subjectConsensus statement
dc.subjectTreatment strategy
dc.subjectDisease activity
dc.subjectDisease-modifying therapy (DMT)
dc.subjectMagnetic resonance imaging (MRI)
dc.titleBrain health: time matters in multiple sclerosis
dc.typejournal-article
dc.typeJournal Article
dc.typeReview
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385323600002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.volume9
plymouth.publication-statusPublished
plymouth.journalMultiple Sclerosis and Related Disorders
dc.identifier.doi10.1016/j.msard.2016.07.003
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeNetherlands
dcterms.dateAccepted2016-07-01
dc.rights.embargodate2017-09-01
dc.identifier.eissn2211-0356
dc.rights.embargoperiod12 months
rioxxterms.versionofrecord10.1016/j.msard.2016.07.003
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2016-09
rioxxterms.typeJournal Article/Review
plymouth.oa-locationhttp://www.sciencedirect.com/science/article/pii/S221103481630102X?via=ihub


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV